Evotec (EVO) – aksjekurser og nyheter

Symboler Symboler	Pris	Endring	Endring (%)	Trend	Forrige pris ved stengetid	Åpne	Høy	Lav	Volum	Markedsverdi
SIXB Materials SIXB Materials	SIXB −0,89%	1 083,04	−9,76	−0,89%	—	1 092,80	1 093,68	1 094,85	1 081,97	—	—
SIXC Communications SIXC Communications	SIXC −0,39%	602,38	−2,36	−0,39%	—	604,74	604,74	605,10	601,34	—	—
SIXE Energy SIXE Energy	SIXE +2,31%	1 242,83	+28,03	+2,31%	—	1 214,80	1 220,81	1 243,82	1 220,81	—	—
SIXI Industrials SIXI Industrials	SIXI −0,62%	1 713,82	−10,75	−0,62%	—	1 724,57	1 727,02	1 732,30	1 707,43	—	—
SIXM Financials SIXM Financials	SIXM +0,09%	639,99	+0,56	+0,09%	—	639,43	641,58	644,53	637,50	—	—
SIXR Staples SIXR Staples	SIXR −0,20%	837,46	−1,69	−0,20%	—	839,15	836,90	840,48	832,89	—	—
SIXRE Real estate SIXRE Real estate	SIXRE −0,65%	214,22	−1,40	−0,65%	—	215,62	215,62	216,21	213,48	—	—
SIXT Technology SIXT Technology	SIXT +0,78%	3 204,38	+24,86	+0,78%	—	3 179,52	3 191,50	3 205,09	3 177,75	—	—
SIXU Utilities SIXU Utilities	SIXU −1,23%	925,38	−11,53	−1,23%	—	936,91	935,42	937,17	923,20	—	—
SIXV Health care SIXV Health care	SIXV −0,69%	1 442,71	−10,06	−0,69%	—	1 452,77	1 445,93	1 447,43	1 434,91	—	—
SIXY Discretionary SIXY Discretionary	SIXY −0,16%	2 361,34	−3,84	−0,16%	—	2 365,18	2 353,64	2 368,10	2 347,80	—	—

EVO:NASDAQ

Evotec

2,98 USD

+1,36%

(+0,040) 1 D

30. apr., 09:33:49 GMT-4 · USD

Alle symboler

1 D

5 D

1 M

6 M

I år

1 Å

5 Å

MAKS

	Symbol	Pris	Endring	Endring (%)

Genererer viktig statistikk for EVO …

Åpne

2,98 USD

Høy

2,98 USD

Lav

2,98 USD

Markedsverdi

1,06 mrd.

Snittvolum

119,42k

Volum

5,83k

52 u høy

4,80 USD

52 u lav

2,31 USD

EPS

−0,34 USD

Beta

1,90

Utestående aksjer

355,76 mill.

Antall ansatte

Relaterte aksjer

Biomarin Pharmaceutical Inc

54,30 USD

+0,17%

VKTX

Viking Therapeutics Inc

30,03 USD

−4,15%

Nyhetssaker

Fra kilder på nettet

AD HOC NEWS

for 3 timer siden

Evotec SE Stock (DE0005664809): Q1 2026 Results Due Today

Stock Titan

for 6 timer siden

Two Gates grants back Evotec push for shorter, safer TB treatment

AD HOC NEWS

for 11 timer siden

Evotec's Boardroom Shuffle Meets Activist Demands Ahead of Make-or-Break Earnings

Investing.com

for 16 timer siden

Evotec nominates Wolfgang Hofmann to supervisory board

Profil

Evotec SE is a publicly listed drug discovery and development company headquartered in Hamburg, Germany. The company operates globally, largely through external alliances with pharmaceutical and biotechnology companies, academic institutions, patient advocacy groups, and venture capitalists. As of 31 December 2021 Evotec had a market capitalization of €7.5 billion and a pipeline of more than 130 partnered programs in discovery, pre-clinical development and clinical development. The company's 4,200+ employees work across a number of therapeutic areas including CNS/neurology, metabolic diseases, Cancer, and inflammatory and infectious diseases. It has long-term discovery alliances with Bristol Myers Squibb, Bayer, Sanofi, Boehringer Ingelheim, the CHDI Foundation, Lilly, Takeda, Sernova, and more. On 28 October 2009 the company was listed on the TecDAX index, which tracks the performance of the 30 largest German companies from the technology sector. On 24 September 2018 Evotec joined the MDAX index, following a rule change that enabled dual listing. The MDAX tracks 60 Prime Standard shares from sectors excluding technology. Wikipedia

Om Evotec

Administrerende direktør-

Ansatte4,47k

Grunnlagt1993

Hovedkontor-

Sektor-

Nettstedevotec.com

Alle verdier i EUR	mars 2025	juni 2025	sep. 2025	des. 2025
Inntekt	199,98 mill.	171,24 mill.	163,89 mill.	253,27 mill.
Varekostnad	172,75 mill.	162,64 mill.	163,95 mill.	174,81 mill.
Direkte driftskostnader	172,75 mill.	162,64 mill.	163,95 mill.	174,81 mill.
Utgifter til forskning og utvikling	10,76 mill.	8,21 mill.	8,71 mill.	9,83 mill.
Totale kostnader til forskning og utvikling	-	-	-	-
Salgskostnader, generelle kostnader og administrative kostnader	47,70 mill.	41,61 mill.	42,31 mill.	44,35 mill.
Driftskostnader	47,04 mill.	37,19 mill.	43,53 mill.	55,25 mill.
Totale driftskostnader	219,79 mill.	199,83 mill.	207,48 mill.	230,06 mill.
Driftsinntekter	−19,82 mill.	−28,60 mill.	−43,59 mill.	23,21 mill.
Andre ikke-operasjonelle inntekter	−6,86 mill.	−10,64 mill.	1,19 mill.	−33,96 mill.
EBT inkludert uvanlige elementer	−29,85 mill.	−43,42 mill.	−42,96 mill.	29,46 mill.
EBT uten uvanlige elementer	−29,66 mill.	−44,67 mill.	−43,36 mill.	18,35 mill.
Kostnad for inntektsskatt	1,73 mill.	59,00k	127,00k	14,84 mill.
Faktisk avgiftssats	−5,78 %	−0,14 %	−0,30 %	50,37 %
Andre driftskostnader	−11,41 mill.	−12,63 mill.	−7,50 mill.	1,07 mill.
Nettoinntekt	−31,58 mill.	−43,48 mill.	−43,09 mill.	14,62 mill.
Netto fortjenestemargin	−15,79 %	−25,39 %	−26,29 %	5,77 %
Resultat per aksje	-	-	−0,24	-
Rente- og investeringsinntekter	-	1,21 mill.	841,00k	11,84 mill.
Rentekostnader	−2,41 mill.	−6,00 mill.	−2,28 mill.	-
Netto rentekostnader	−2,41 mill.	−4,79 mill.	−1,44 mill.	11,84 mill.
Avskrivnings- og amortiseringskostnader	-	-	-	-
EBITDA	76,50k	−3,42 mill.	−18,27 mill.	41,91 mill.
Gevinst eller tap ved salg av eiendeler	-	-	-	-

AI-innhold kan inneholde feil. Finn ut mer

HjelpSend tilbakemeldingPersonvern Vilkår Ansvarsfraskrivelse

Finance

Utforskning